Search
Search Results
-
The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
ObjectiveTreatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional...
-
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)
BackgroundLittle is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or...
-
Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer
PurposeTo investigate the potential clinical importance of continuing immunotherapy beyond progression in patients with advanced non-small-cell lung...
-
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
PurposeEverolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(−) advanced breast cancer (aBC)...
-
Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol
BackgroundArteriosclerosis and atherosclerosis are closely related with cardiovascular disease (CVD) risk. Remnant cholesterol (RC) could predict...
-
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
BackgroundThere has been no clinical evidence to justify continued pembrolizumab therapy beyond progression in patients with metastatic urothelial...
-
Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence
Immunotherapy (ITH) holds the possibility of tumor burden decrease after initial RECIST 1.1 defined progression. The clinical concept of treating...
-
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment
Background and ObjectiveUnderstanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world...
-
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
PurposePanitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of...
-
Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
Based on the results of the pivotal CLARITY study, cladribine tablets were approved for use in the European Union in 2017 as a high-efficacy therapy...
-
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
BackgroundDespite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR -mutated NSCLC. This study...
-
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Ovarian cancer is the leading cause of gynecological cancer death. Improved understanding of the biologic pathways and introduction of poly...
-
Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial
BackgroundMany previous studies evaluated a combination of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) for...
-
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
BackgroundATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with...
-
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
Purpose of ReviewThis review provides a comprehensive assessment of recent literature reports describing atypical response patterns observed with...
-
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patients with metastatic epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the...
-
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond
In the era of precision medicine, the optimization of oncological patient management with early and accurate tumor response assessment is crucial. In...
-
A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations
Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and...
